Overview
Anaplastic thyroid carcinoma (ATC) is a rare, aggressive malignancy characterized by rapid growth and poor prognosis. It often presents with a stony neck mass and requires urgent diagnostic evaluation and multidisciplinary management 1.Diagnosis
Clinical suspicion: Rapid growth, stony neck mass 1.
Diagnostic work-up: Urgent imaging (e.g., CT, MRI), fine-needle aspiration biopsy, and histopathological examination 1.
Morphologic patterns: Spindle, giant cell, squamoid; often with epithelial differentiation confirmed via immunohistochemistry (cytokeratin staining) 3.
Immunohistochemistry: Useful for diagnosis; CEA positivity noted in squamoid variants 3.
Dedifferentiated component: One-third of tumors may have a better-differentiated component 3.
Exclusion criteria: Small cell tumors should not be classified as anaplastic 3.Management
First-line treatment: Multidisciplinary assessment including potential use of tyrosine kinase inhibitors (TKIs) such as lenvatinib, sorafenib, and combinations like dabrafenib plus trametinib 12.
Targeted therapies: Anlotinib, pembrolizumab plus TKIs (e.g., dabrafenib, trametinib, lenvatinib) 2.
Immunotherapy: Pembrolizumab in combination with TKIs 2.
Supportive care: Essential alongside active treatment, involving palliative care consultation 1.
Palliative care: Recommended from the outset, considering patient wishes and comorbidities 1.
Real-world efficacy: Pooled median overall survival (OS) and progression-free survival (PFS) around 6-7 months with TKI treatments 2.Special Populations
Elderly patients: Multidisciplinary assessment must consider general health status and comorbidities 1.
Comorbidities: Management should integrate support care and geriatric oncology input as needed 1.Key Recommendations
Urgent diagnostic evaluation upon clinical suspicion of ATC to enable prompt treatment (Evidence: Strong 1).
Multidisciplinary team involvement including specialists, support care, and geriatric oncology if necessary, tailored to disease extent and patient status (Evidence: Strong 1).
Incorporate realistic prognosis discussions with patients and families, offering either active treatment with supportive care or exclusive palliative care (Evidence: Expert opinion 1).
Consider tyrosine kinase inhibitors and immunotherapy as part of treatment strategies, given their role in real-world efficacy despite limited prospective study data (Evidence: Moderate 2).References
1 Lamartina L, Jannin A, Decaussin-Petrucci M, Bardet S, Escande A, Ciappuccini R et al.. ENDOCAN TUTHYREF network consensus recommendations: Anaplastic thyroid cancer. Annales d'endocrinologie 2025. link
2 Kuang BH, Zhang WX, Lin GH, Fu C, Cao RB, Wang BC. Tyrosine kinase inhibitors in patients with advanced anaplastic thyroid cancer: an effective analysis based on real-world retrospective studies. Frontiers in endocrinology 2024. link
3 Carcangiu ML, Steeper T, Zampi G, Rosai J. Anaplastic thyroid carcinoma. A study of 70 cases. American journal of clinical pathology 1985. link